Today's Date
Mechanistic Studies in a Phase II Trial of Multiple Sclerosis with Altered Peptide Ligand (APL)
(
)
ITN Protocol #:
ITN505AI
Branded Name:
Treatment Protocol #:
Therapeutic Area:
Autoimmune Disease
Current Status:
Complete
Summary:
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of NBI-5788 in Patients with Relapsing Multiple Sclerosis
Clinical Operations Manager
Study Personnel:
